Valiant Laboratories Ltd IPO
Open Demat Account
Valiant Laboratories Ltd IPO Details
Details
| Total Shares Offered | Offer to Public | Retail Max (Shares) | Pre Issue Promoters Holding | Exchange | Issue size |
|---|---|---|---|---|---|
| ₹ 108.9 L | TBA | ₹ 38.12 L | ₹ 268.68 L | BSE | ₹ 152.46 Cr |
| IPO Open Date | Close Date | Lot Size | Min Investment | Issue Type | Listing Date |
| 27 Sep, 23 | 03 Oct, 23 | 105 | ₹ 13,965 | Book Building | 06 Oct, 23 |
Valiant Laboratories Ltd IPO Dates
Details
| Sector | Type |
|---|---|
| Sector | Pharmaceuticals - Indian - Bulk Drugs & Formln |
| Sub Sector | NA |
| Issue Type | Book Building |
Subscription Status
*Values are in Lakhs
| Investor Type | Subscription Times | Shares Offered* | Shares Bid* |
|---|---|---|---|
| QIB | 0x | 5445000 | 0 |
| NII | 0x | 1633500 | 0 |
| Retail | 0x | 3811500 | 0 |
| Employee | 0x | 0 | 0 |
| Total | 0x | 10890000 | 0 |
Subscription Status
Investor Type
QIB
NII
Retail
Employee
Total
*Values are in Lakhs
Valiant Laboratories Ltd Financial Status
Income Statement
Balance Sheet
| Particulars (in Rs. Crores) | FY23 | FY22 | FY21 |
|---|---|---|---|
| Revenue from operations | 182.06 | 333.91 | 44.19 |
| EBITDA | 3.15 | 41.26 | 46.68 |
| PAT | 0.34 | 29.00 | 27.50 |
| Total Assets | 172.33 | 148.06 | 156.40 |
| Share Capital | 43.45 | 32.56 | 16.28 |
| Total Borrowings | 79.28 | 105.39 | 10.97 |
| Operating Activities (Net Cash) | 2.29 | 30.56 | 29.99 |
| Investing Activities (Net Cash) | 118.37 | 33.98 | -1.05 |
| Financing Activities (Net Cash) | 79.28 | 105.39 | 10.97 |
| Net Cashflow | 96.72 | 0.46 | 20.13 |
Particulars (in Rs. Crores)
Revenue from operations
EBITDA
PAT
Total Assets
Share Capital
Total Borrowings
Operating Activities (Net Cash)
Investing Activities (Net Cash)
Financing Activities (Net Cash)
Net Cashflow
About Valiant Laboratories Ltd
Valiant Laboratories Limited was originally formed as a partnership firm under the name and style of `M/s. Bharat Chemicals' pursuant to the deed of partnership dated October 17, 1980, amended and restated from time to time. Subsequently, the partnership firm, M/s. Bharat Chemicals was converted into a public limited company under the provisions of the Companies Act with the name Valiant Laboratories Limited pursuant to certificate of incorporation dated August 16, 2021 issued by the by Central Registration Centre, Registrar of Companies.
The Company operates in the pharmaceutical API industry. The pharmaceutical API industry in India is ranked third-largest globally in terms of volume. The paracetamol API industry (Domestic consumption+ exports) grew from Rs. 22 billion in fiscal 2017 to Rs. 39 billion in fiscal 2023. Going forward the paracetamol API industry is expected to clock a CAGR of 5-7% between fiscal 2023 and fiscal 2027, largely driven by the demand from domestic formulation manufacturers as well as export markets.
Valiant Laboratories Limited is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. Bulk drugs/Active Pharmaceutical Ingredients (API) serve as raw materials for manufacturing finished dosage forms or formulations. Paracetamol (Scientific name: Acetaminophen or para-hydroxyacetanilide - C8H9NO2), is one of the most commonly taken analgesic worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO). Paracetamol has several applications such as usage in treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold and fever. We manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of our customers.
Peer Comparison:
- Granules India Ltd
- Jagsonpal Pharmaceuticals Ltd
- Alkyl Amines Chemicals Ltd
- Laxmi Organic Industries Ltd
Valiant Laboratories Ltd IPO Key Points
Strengths
- Experienced promoter and strong management team:
- Strong Focus on Sustainability in Operations:
- Strategically located manufacturing facility:
- Quality-Focused Compliant Manufacturing and R&D Infrastructure:
- Reducing dependence on import of raw materials:
Risk
- The company is subject to strict quality requirements, regular inspections and audits by its customers and any failure to comply with quality standards may lead to cancellation of existing and future orders and could negatively impact the company business, financial condition, results of operations and prospects it may impact the reputation as well.
- The company does not have long-term agreements with its suppliers for raw materials and an inability to procure the desired quality, quantity of its raw materials in a timely manner and at reasonable costs, or at all, may have a negative impact on the business, results of operations, financial condition and cash flows.
- If there are delays in setting up the Proposed Facility or if the costs of setting up and the possible time or cost overruns related to the Proposed Facility or the purchase of plant and machinery for the Proposed Facility are higher than expected, it could have a material adverse effect on its financial condition, results of operations and growth prospects.
Strategy
- Diversification into new chemistries and industry.
- Increase in market share.
- Improve operational efficiencies through backward integration of Proposed Facility:
- Increase its penetration into international markets including regulated markets.
- Experienced promoter and strong management team:
- Strong Focus on Sustainability in Operations:
- Strategically located manufacturing facility:
- Quality-Focused Compliant Manufacturing and R&D Infrastructure:
- Reducing dependence on import of raw materials:
How To Apply for Valiant Laboratories Ltd IPO Online?
Step 1:
Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.
Step 2:
From the list of open IPOs, select the IPO you want to invest.
Step 3:
Go through the IPO details like lot size, price band, about the company, etc.
Step 4:
Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.
Step 5:
Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.
